...
首页> 外文期刊>Journal of Inorganic Biochemistry: An Interdisciplinary Journal >Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer
【24h】

Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer

机译:金属基抗体药物缀合物。 癌症中申请中的潜在和挑战是癌症的靶向疗法

获取原文
获取原文并翻译 | 示例

摘要

Antibody drug conjugates have emerged as a very attractive type of targeted therapy in cancer. They combine the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutics. This review focuses on antibody drug conjugates based on metal-containing cytotoxic payloads. We will also describe antibody drug conjugates (ADCs) in which a metal-based component (mostly metallic nano particles) exerts a relevant function in the ADC (for photodynamic or photothermal therapy, as air-plasma enhancer or chemo-sensitizer, as carrier of other cytotoxic payloads or as an integral part of the linker structure). Challenges and opportunities to increase the translational potential of these ADCs will be discussed.
机译:抗体药物缀合物已经出现为癌症中具有非常有吸引力的靶向治疗。 它们将单克隆抗体(mAb)的抗原靶向特异性与化学治疗剂的细胞毒性效力相结合。 该综述侧重于基于含金属的细胞毒性有效载荷的抗体药物缀合物。 还将描述抗体药物缀合物(ADC),其中金属基组分(主要是金属纳米颗粒)在ADC中施加相关功能(用于光动力或光热疗法,作为空气血浆增强剂或化学敏化剂,作为载体 其他细胞毒性有效载荷或作为接头结构的组成部分)。 将讨论增加这些ADC的翻译潜力的挑战和机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号